RAD140

ID: rad140

Aliases: Testolone, Vosilasarm, EP0062, RAD-140

Type: compound

Route/form: oral investigational drug in published studies

Status: investigational

Evidence level: early human

Best data tier: early human + case-report/safety + disease-context

Support scope: human, non-human/mechanistic

Source types: case_report, early_human, preclinical

Linked sources: 5

Broad outcomes: Fat loss / metabolic health, Hormones / fertility / sexual health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• androgen receptor modulator
• nonsteroidal SARM

Optimization domains

• SARM
• breast cancer
• muscle wasting
• body composition
• doping

Research basis

• RAD140 has first-in-human oncology phase 1 data in ER-positive/HER2-negative metastatic breast cancer and preclinical work supporting oral SARM pharmacology.
• It belongs as a clinically touched SARM, but the human evidence is oncology signal/safety rather than gym performance.
• Including negative mouse adaptation and liver-injury case reports keeps the entry from reading like a one-way anabolic claim.

Limits, risks, and missing evidence

• Human data are oncology-focused and do not validate gym-cycle outcomes, dosing, stacking, or PCT assumptions.
• Preclinical data include negative skeletal-muscle adaptation/frailty/mortality signals in female mice, so the biology is not simply anabolic equals better.
• Androgenic signaling, liver injury reports, metabolic effects, and HPG-axis suppression remain class concerns.

Risk flags

• investigational
• sarm class risk
• liver injury reports
• endocrine suppression possible
• doping
• disease context human data

Linked papers, labels, and reviews

1. First-in-human phase 1 study of RAD140 in ER+/HER2- metastatic breast cancer
   early_human / pubmed_rad140_phase1_breast_cancer_2022
   Oncology phase 1 study of oral RAD140/vosilasarm.
2. Design, synthesis, and preclinical characterization of RAD140
   preclinical / pubmed_rad140_preclinical_2010
   Discovery and preclinical characterization of RAD140 as a SARM.
3. RAD140 negatively impacts skeletal muscle adaptation, frailty status and mortality risk in female mice
   preclinical / pubmed_rad140_muscle_adaptation_mouse_2023
   Preclinical RAD140 study reporting negative adaptation/frailty/mortality signals in female mice; important counter-signal for performance claims.
4. RAD-140 Drug-Induced Liver Injury
   case_report / pubmed_rad140_dili_case_2022
   RAD-140 DILI case report; risk anchor for off-label/research-chemical use.
5. Drug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033)
   case_report / pubmed_rad_lgd_dili_case_2020
   Case report involving RAD-140 and RAD-140/LGD-4033 product exposure; useful for SARM liver-risk context.